norucholic acid
Phase 3Small molecule
norucholic acid is one of 11 small molecule programs targeting Sclerosing Cholangitis. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Sclerosing Cholangitis
#DrugCompanyPhaseTrials
1Vancocin
HHikma Pharmaceuticals LLC
Approved
Actigall
AbbVieApproved
Retin-a
VValeant Pharmaceuticals
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Mitosol
UUroGen Pharma Ltd.
Approved
Zocor
OOrganon and Co
Phase 3
Crestor
AstraZenecaPhase 1
CS0159
CCascade Pharmaceuticals, Inc
Phase 2
norucholic acid
DDr. Falk Pharma GmbH
Phase 3
Hymecromone
SStanford University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sclerosing Cholangitis1 trial
Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC)
Not yet recruiting·—·Phase 3·NCT06886360·120 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for norucholic acid. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- DDr. Falk Pharma GmbH